Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White Paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

White Paper

Global Pharma Pricing and Market Effects of President Trump’s Proposed Policies

President Trump campaigned to use the buying power of the federal government to directly negotiate downward the prices of drugs used by Medicare patients. The question this white p ...

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

Blog

Implications From HEOR And RWE Models For Biopharmaceutical Commercial Analytics

The following blog is an expanded summary of proposed research accepted for delivery at the upcoming 22nd ISPOR Annual International Meeting, Research Poster Presentations – ...

Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White Paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Econometric Analysis Of Biopharmaceutical Transfer Pricing

White Paper

Econometric Analysis Of Biopharmaceutical Transfer Pricing

The shift to commercializing specialty medicines, where market performance will be predicated on the demonstration and delivery of scientific evidence, will mean the importance of ...

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

White Paper

Pharma Sales And Marketing Restrictions – Has the Pendulum Swung Too Far?

The question this commentary asks is simply this – has the pendulum swung too far in the direction of excessive restrictions on sales and marketing practices of biopharmaceut ...

Patient Claims Versus EHR Data – How To Choose Between The Two?

White Paper

Patient Claims Versus EHR Data – How To Choose Between The Two?

The topics this white paper will review are which dataset is more appropriate for answering certain types of business questions, look at some cases from the academic literature tha ...

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

White Paper

Is Biopharmaceutical Industry Drug Demand Becoming More Recession Sensitive?

The Great Recession in the U.S. not only marked a period of the longest and by many measures the largest economic downturn since The Great Depression of the 1930’s, but also alte ...

The Relationship Between Drug Price Controls And Patient Health Outcomes

White Paper

The Relationship Between Drug Price Controls And Patient Health Outcomes

No long-term “solution” on drug pricing has emerged gaining broad consensus among public policy officials and politicians, patient advocacy groups, medical and health service r ...

Do You Know The Answers To Your Important Territory Alignment Questions

White Paper

Do You Know The Answers To Your Important Territory Alignment Questions

Do you know the answers to your important territory alignment questions? Or put another way, do you approach answering questions on your territory alignment issues like the blind s ...

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The Changing Role Of Pharma Sales And Marketing In A Specialty Medicine Environment

The growing shift to specialty medicines in the US pharma market is well documented. Pricing issues are becoming more common and controversial, with questions being raised about th ...

No more posts to display!
Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...